FDA committee votes against Eli Lilly cancer treatment over concerns trials conducted only in China

FDA committee members said the trial population of mostly Asian men did not represent the diversity of U.S. patients.

from Health and Science https://ift.tt/XoRBV0E
https://ift.tt/4ajfIVs
https://ift.tt/3q1HIwc